Did management comment on any macro‑economic or regulatory risks that could affect future performance?

Based on the information that has been supplied, no comment from Coloplast’s management about macro‑economic or regulatory risks is included.

The excerpt you provided is simply an announcement of the upcoming earnings‑release conference call (date, time, webcast details, and a note that the presentation will be posted on the company website). It does not contain any verbatim statements, excerpts from the management discussion, or summaries of the topics that will be covered during the call.

Therefore, with the material at hand we cannot say whether management will—or will not—address macro‑economic or regulatory risk factors. To obtain that information you would need to:

1. Review the full interim results press release (the 9‑month 2024/25 earnings release itself often includes a “Management Commentary” or “Outlook” section where such risks are disclosed).
   
2. Listen to or read the transcript of the conference call (or the accompanying slide deck), where analysts typically ask about macro‑economic conditions, inflation, currency effects, healthcare‑policy changes, etc.
   
3. Check any subsequent investor‑relations materials (e.g., a “Risk Factors” annex, the company’s FY2024/25 annual report, or regulatory filings) that may elaborate on exposure to economic slow‑downs, reimbursement reforms, or other regulatory developments.

In short, the announcement you have does not contain any management commentary on macro‑economic or regulatory risks; you’ll need to consult the actual earnings release, call transcript, or related filings for that detail.